Macy Bailey
Primary Care · Columbus, OHNPI 1760126700
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 150 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 21.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,235 and has fallen 51.5% since, to $599 in 2024.
Across 150 payments — averaging $16.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$547
- AstraZeneca$362
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$325
- Otsuka America Pharmaceutical, Inc.$185
- Dexcom, Inc.$168
- Phathom Pharmaceuticals, Inc.$83
- plus $828 from 22 others
What the payments were for
- Food & beverage$2,498100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 39 | $547 |
| AstraZeneca | 24 | $362 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 20 | $325 |
| Otsuka America Pharmaceutical, Inc. | 11 | $185 |
| Dexcom, Inc. | 9 | $168 |
| Phathom Pharmaceuticals, Inc. | 4 | $83 |
| Mylan Specialty L.p. | 3 | $78 |
| Pfizer | 4 | $76 |
| Exact Sciences | 3 | $70 |
| Lilly USA, LLC | 4 | $59 |
| Amgen | 3 | $53 |
| Astellas Pharma US Inc | 3 | $52 |
| Axsome Therapeutics, Inc. | 2 | $48 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $47 |
| Boehringer Ingelheim | 3 | $41 |
| Xeris Pharmaceuticals, Inc. | 2 | $38 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $34 |
| Lifescan, Inc. | 1 | $30 |
| Cequr Corporation | 1 | $29 |
| Bayer | 2 | $26 |
| Nevro Corp. | 1 | $24 |
| Medicomp Inc | 1 | $22 |
| Nestle Healthcare Nutrition Inc. | 1 | $20 |
| Indivior Inc. | 1 | $18 |
| Lundbeck LLC | 1 | $18 |
| Sanofi-aventis U.S. LLC | 1 | $17 |
| Ironwood Pharmaceuticals, Inc | 1 | $14 |
| Hikma Pharmaceuticals USA | 1 | $14 |
How this compares
$2,498 in reported general payments places this provider in the 85th percentile of 321 primary care providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 77 | $45,262 |
| TrulicityDulaglutide | 20 | $19,346 |
| JardianceEmpagliflozin | 28 | $16,931 |
| LinzessLinaclotide | 29 | $16,327 |
| OzempicSemaglutide | 14 | $13,396 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 27 | $11,403 |
| Ondansetron Hcl | 75 | $10,867 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 21 | $10,801 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 17 | $10,726 |
| VascepaIcosapent Ethyl | 30 | $10,534 |
| MyrbetriqMirabegron | 19 | $9,607 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 14 | $9,226 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 417 | $8,670 |
| EliquisApixaban | 13 | $7,667 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 101 | $7,417 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Bevespi Aerosphere, Breztri Aerosphere, Symbicort | $362 | $71,188138 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat, Tradjenta | $41 | $29,77653 claims |
| Lilly USA, LLCTrulicity | $59 | $19,34620 claims |
| AbbVieLinzess | $547 | $16,32729 claims |
| Astellas Pharma US IncMyrbetriq | $52 | $9,60719 claims |
| PfizerEliquis | $76 | $7,66713 claims |
| Hikma Pharmaceuticals USABuprenorphine-Naloxone | $14 | $6,44746 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 321 primary care providers in Ohio.
Other primary care in Columbus
- Joseph PriceColumbus$6K
- Madison WaltersColumbus$6K
- Jordyn WilsonColumbus$4K
- Christopher BaranColumbus$3K
- Stephanie HoheiselColumbus$2K
- Sheila CaniniColumbus$2K
- Sarah AndersonColumbus$2K
- Shireen ShattiColumbus$2K
- Adine EdwardsSpringfield$14K
- Kelly McKenna TaulbeeHamilton$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.